CN101182321A - Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof - Google Patents
Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof Download PDFInfo
- Publication number
- CN101182321A CN101182321A CNA2007100323563A CN200710032356A CN101182321A CN 101182321 A CN101182321 A CN 101182321A CN A2007100323563 A CNA2007100323563 A CN A2007100323563A CN 200710032356 A CN200710032356 A CN 200710032356A CN 101182321 A CN101182321 A CN 101182321A
- Authority
- CN
- China
- Prior art keywords
- indolizino
- azanaphthalenes
- preparation
- indolizine
- naphthoquinone derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- -1 Indolizine heterocyclic nitrogen naphthoquinone derivatives Chemical class 0.000 title claims abstract description 8
- 230000001093 anti-cancer Effects 0.000 title abstract description 4
- 229930192627 Naphthoquinone Natural products 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000002791 naphthoquinones Chemical class 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 239000003560 cancer drug Substances 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- TZMFJUDUGYTVRY-UHFFFAOYSA-N pentane-2,3-dione Chemical compound CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 13
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical class C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 abstract 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
- 150000004059 quinone derivatives Chemical class 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 150000004053 quinones Chemical class 0.000 description 4
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical class C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention discloses an indolizine and nitrogen heterocyclic naphthoquinone derivative, a preparation method and an anticancer application thereof. The structure of the indolizine and nitrogen heterocyclic naphthoquinone derivative is shown as a formula (I). The preparation method is that 6, 7-dichloro nitrogen heterocyclic naphthoquinone and active methylene reagent are put in to anhydrous alcohol, and pyridine derivative is added under stirring for the reflux reaction for 5 to 20 hours; the reaction finished for cooling, solid is separated out to be filtered and processed for the chromatographic separation by silicon gel column to obtain the target compound. The indolizine and nitrogen heterocyclic naphthoquinone derivative has obvious inhibitory effect towards various kinds of tumour cells, has comparatively small virulence towards the normal cell and has the prospect of preparing for the anticancer medicine.
Description
Technical field
The present invention relates to a class indolizino azanaphthalenes quinone derivative and the purposes in preparation treatment cancer drug thereof.
Background technology
Tumour is the principal disease that threatens human health and life security.The research and development of new type antineoplastic medicine are the important research field that chemist and medicine scholar pay close attention to always.
Camptothecine is a class natural alkaloid, has good antineoplastic activity.Discover that camptothecine is mainly by suppressing topoisomerase 1 (TOP1) the performance antitumous effect in the tumour cell.But the anti-tumor activity of camptothecine is still undesirable, if can carry out structural modification to it, strengthens its anti-tumor activity, and application prospect is with boundless.
Summary of the invention
The purpose of this invention is to provide the new indolizino azanaphthalenes quinone derivative of a class.
Another object of the present invention provides the application of above-mentioned indolizino azanaphthalenes quinone derivative in preparation treatment cancer drug.
The indolizino azanaphthalenes quinone derivative that the present invention relates to is suc as formula shown in (I):
Wherein, M, X, Y and Z are CH or N respectively;
R
1Be selected from following radicals: H, C respectively
1-C
4Alkyl, COOCH
3, COOC
2H
5, COOC
3H
7, COOC
4H
9, COCH
3, COC
2H
5, COC
3H
7, COC
4H
9, CN or aromatic base;
R
2Be selected from following radicals: H, F, Cl, Br, OH, NH respectively
2, COOH or C
1-C
4Alkyl;
R
3Be selected from following radicals: H, F, Cl, Br, OH, COOH or C respectively
1-C
4Alkyl.
Indolizino azanaphthalenes quinone derivative of the present invention can obtain by the method for chemosynthesis, can obtain (II) by following reaction.
With 6,7-dichloro azepine naphthoquinones and active methylene group reagent join in the dehydrated alcohol, stir to add pyridine derivate, back flow reaction 5~20 hours down; Stop, cooling has solid to separate out; Filter, the solid that obtains obtains target compound with the silica gel column chromatography separation.In this reaction, can obtain a pair of isomer A and B simultaneously, or single product (being that product A is identical with B).
Described active methylene group reagent is Acetacetic acid alkyl ester, itrile group ethyl acetate, methyl ethyl diketone or nitroparaffins.
Show by the tumor cell in vitro inhibition test, indolizino azanaphthalenes quinone derivative of the present invention has obvious inhibiting activity to various tumor cell strains as GLC-82 (human lung adenocarcinoma cell), NCI-H460 (National People's Congress's cell lung cancer cell), HL-60 (people's promyelocytic leukemia cancer cells) and human breast cancer cell (MCF-7) etc.Animal acute toxicity experiment shows that the acute toxicity of this compounds is very low, LD
50Greater than 2.2g/kg mouse body weight.Therefore indolizino azanaphthalenes quinone derivative of the present invention can be used to prepare antitumor drug.Indolizino azanaphthalenes quinone derivative can with pharmaceutically acceptable auxiliary, make injection, tablet, pill, capsule, suspension agent or emulsion or the like.Its form of medication can through oral, through skin, vein or intramuscular injection.
Compared with prior art, the present invention has following beneficial effect:
The present invention is based on the camptothecine mother nucleus structure, and a series of indolizino azanaphthalenes quinoness have been synthesized in design, find that this compounds has very strong inhibition activity to TOP1.Experiment showed, that further the indolizino azanaphthalenes quinones that the present invention relates to has the obvious suppression effect to kinds of tumor cells.Less relatively to normal cytotoxicity, have preparation cancer therapy drug prospect.
Embodiment
Embodiment 1, indolizino azanaphthalenes quinone derivative NP1-A and NP1-B's is synthetic
With 6 of 0.01mol, 7-two chloro-5,8-quinolyl dione and 0.04mol methyl aceto acetate join in 20~80ml dehydrated alcohol, stir the 3-fluorine pyridine that adds 0.01~0.08mol down, back flow reaction 5~20 hours.Stop, cooling has solid to separate out.Filter, the solid that obtains separates with silica gel column chromatography, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP1-A and NP1-B simultaneously.
NP1-A: productive rate is 12%; M.p.=197-200 ℃; ESI:339.0 (100%), 340.1 (20%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.64 (d, 1H, J=6.8Hz), 9.06 (dd, 1H, J=4.8,1.6Hz), 8.54 (dd, 1H, J=8.0,1.6Hz), 7.67 (dd, 1H, J=8.0,4.8Hz), 7.16-7.06 (m, 2H), 4.54 (q, 2H, J=7.2Hz), 1.47 (t, 3H, J=7.2Hz).
NP1-B: productive rate is 18%.m.p.=200-202 ℃; ESI:339.0 (100%), 340.1 (20%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.49 (dd, 1H, J=6.3,1.2Hz), 9.00 (dd, 1H, J=4.7,1.7Hz), 8.57 (dd, 1H, J=7.8,1.8Hz), 7.68 (dd, 1H, J=7.8,4.5Hz), 7.14-7.03 (m, 2H), 4.54 (q, 2H, J=7.2Hz), 1.48 (t, 3H, J=7.2Hz).
The structural formula of NP1-A and NP1-B is as follows respectively:
Embodiment 2, indolizino azanaphthalenes quinone derivative NP2-A and NP2-B's is synthetic
Method is with embodiment 1, and different is to replace methyl aceto acetate with nitroethane, replaces 3-fluorine pyridine with pyridine, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP2-A and NP2-B simultaneously.
NP2-A: productive rate is 19%; M.p.=233 ℃; ESI:263.3 (100%) [M+1]
+ 1HNMR (300MHz, CDCl
3, TMS): δ 9.77 (d, 1H, J=6.6Hz), 8.99 (d, 1H, J=3.0Hz), 8.49 (d, 1H, J=7.5Hz), 7.67 (d, 1H, J=9.0Hz), 7.57 (dd, 1H, J=7.4,4.8Hz), 7.27 (t, 1H, J=7.4Hz), 7.11 (t, 1H, J=6.6Hz), 2.70 (s, 3H).
NP2-B: productive rate is 15%; M.p.=238 ℃; ESI:263.3 (100%) [M+1]
+ 1HNMR (300MHz, CDCl
3, TMS): δ 9.64 (d, 1H, J=6.6Hz), 8.94 (d, 1H, J=2.6Hz), 8.58 (d, 1H, J=7.5Hz), 7.69 (d, 1H, J=9.0Hz), 7.63 (dd, 1H, J=7.4,4.8Hz), 7.26 (t, 1H, J=7.4Hz), 7.10 (t, 1H, J=6.6Hz), 2.74 (s, 3H).
The structural formula of NP2-A and NP2-B is as follows respectively:
Embodiment 3, indolizino azanaphthalenes quinone derivative NP3-A and NP3-B's is synthetic
Method is with embodiment 1, and different is to replace 3-fluorine pyridine with pyridine, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP3-A and NP3-B simultaneously.
NP3-A: productive rate is 31%; M.p.=226-227 ℃; ESI:321.2 (100%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.92 (d, 1H, J=7.2Hz), 9.01 (d, 1H, J=3.9Hz), 8.54 (d, 1H, J=7.5Hz), 8.34 (d, 1H, J=9.0Hz), 7.64 (dd, 1H, J=7.5,4.5Hz), 7.49 (t, 1H, J=8.0Hz), 7.24 (t, 1H, J=6.9Hz), 4.52 (q, 2H, J=7.1Hz), 1.51 (t, 3H, J=7.1Hz).
NP3-B: productive rate is 12%; M.p.=200-201 ℃; ESI:321.2 (100%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.78 (d, 1H, J=6.9Hz), 8.99 (d, 1H, J=3.6Hz), 8.55 (d, 1H, J=7.8Hz), 8.38 (d, 1H, J=9.0Hz), 7.65 (dd, 1H, J=7.8,4.5Hz), 7.47 (ddd, 1H, J=8.7,6.9,0.9Hz), 7.20 (td, 1H, J=6.9,1.2Hz), 4.50 (q, 2H, J=7.2Hz), 1.52 (t, 3H, J=7.2Hz).
The structural formula of NP3-A and NP3-B is as follows:
Embodiment 4, indolizino azanaphthalenes quinone derivative NP4-A and NP4-B's is synthetic
Method is with embodiment 1, and different is to replace methyl aceto acetate with methyl ethyl diketone, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP4-A and NP4-B simultaneously.
NP4-A: productive rate is 13%; M.p.=252 ℃; ESI:291.2 (100%) [M+1]
+ 1HNMR (300MHz, CDCl
3, TMS): δ 9.93 (d, 1H, J=6.9Hz), 9.03 (d, 1H, J=3.6Hz), 8.53 (d, 1H, J=7.8Hz), 8.46 (d, 1H, J=9.3Hz), 7.66 (dd, 1H, J=7.7,4.7Hz), 7.51 (t, 1H, J=7.8Hz), 7.25 (t, 1H, J=7.5Hz), 2.88 (s, 3H).
NP4-B: productive rate is 2.5%; M.p.=234 ℃; ESI:291.2 (100%) [M+1]
+ 1HNMR (300MHz, CDCl
3, TMS): δ 9.80 (d, 1H, J=6.8Hz), 8.99 (d, 1H, J=3.6Hz), 8.56 (dd, 1H, J=7.8,1.5Hz), 8.46 (d, 1H, J=9.0Hz), 7.67 (dd, 1H, J=7.7,4.7Hz), 7.49 (ddd, 1H, J=8.6,6.9,1.2Hz), 7.23 (td, 1H, J=6.9,1.2Hz), 2.91 (s, 3H).
The structural formula of NP4-A and NP4-B is as follows respectively:
Embodiment 5, indolizino azanaphthalenes quinone derivative NP5-A and NP5-B's is synthetic
Method is with embodiment 1, and different is to replace 3-fluorine pyridine with the 3-chloropyridine, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP5-A and NP5-B simultaneously.
NP5-A: productive rate is 16%; M.p.=185-190 ℃; ESI:355.2 (100%), 357.3 (33%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.58 (d, 1H, J=6.9Hz), 8.98 (d, 1H, J=4.5Hz), 8.57 (d, 1H, J=7.5Hz), 7.67 (dd, 1H, J=7.8,4.5Hz), 7.36 (d, 1H, J=7.5Hz), 7.07 (t, 1H, J=7.2Hz), 4.56 (q, 2H, J=7.2Hz), 1.49 (t, 3H, J=7.2Hz).
NP5-B: productive rate is 12%; M.p.=195 ℃; ESI:355.2 (100%), 357.3 (33%) [M+1]
+ 1H NMR (300MHz, CDCl
3, TMS): δ 9.72 (d, 1H, J=6.3Hz), 9.03 (d, br, 1H, J=3.3Hz), 8.52 (d, 1H, J=7.2Hz), 7.65 (dd, 1H, J=7.8,4.6Hz), 7.38 (d, 1H, J=7.2Hz), 7.09 (t, 1H, J=7.2Hz), 4.55 (q, 2H, J=7.2Hz), 1.47 (t, 3H, J=7.2Hz).
The structural formula of NP5-A and NP5-B is as follows respectively:
Embodiment 6, indolizino azanaphthalenes quinone derivative NP6-A and NP6-B's is synthetic
Method is with embodiment 1, and different is to replace 3-fluorine pyridine with the 3-aminopyridine, obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP6-A and NP6-B simultaneously.
NP6-A: productive rate is 24%; M.p.=195-200 ℃; ESI[M+1]
+: 336.2 (100%);
1H NMR (300MHz, DMSO-d6, TMS): δ 9.16 (d, 1H, J=6.6Hz), 8.95 (d, 1H, J=3.6Hz), 8.38 (d, 1H, J=7.8Hz), 7.75 (dd, 1H, J=7.8,3.6Hz), 7.18 (t, 1H, J=6.9Hz), 6.70 (d, 1H, J=7.5Hz), 6.04 (s, br, 2H), 4.41 (q, 2H, J=6.9Hz), 1.38 (t, 3H, J=6.9Hz).
NP6-B: productive rate is 24%; M.p.=323 ℃; ESI[M+1]
+: 336.2 (100%);
1HNMR (300MHz, DMSO-d6, TMS): δ 9.11 (d, 1H, J=6.6Hz), 8.92 (dd, 1H, J=4.5,1.8Hz), 8.46 (dd, 1H, J=7.8,1.5Hz), 7.81 (dd, 1H, J=7.8,4.8Hz), 7.19 (dd, 1H, J=7.5,6.6Hz), 6.71 (d, 1H, J=7.5Hz), 4.42 (q, 2H, J=7.1Hz), 1.38 (t, 3H, J=7.1Hz).
The structural formula of NP6-A and NP6-B is as follows respectively:
Embodiment 7, indolizino azanaphthalenes quinone derivative NP7-A and NP7-B's is synthetic
Method is with embodiment 2, and different is to replace nitroethane with Nitromethane 99Min., obtains a pair of indolizino azanaphthalenes quinone derivative isomer NP7-A and NP7-B simultaneously.
NP7-A: productive rate is 13%; ESI[M+1]
+: 294.3 (100%);
1H NMR (300MHz, CDCl
3, TMS): δ 9.74 (d, 1H, J=5.7Hz), 9.02 (s, br, 1H, J=4.5Hz), 8.51 (d, 1H, J=6.9Hz), 7.71 (d, 1H, J=7.5Hz), 7.50-7.75 (m, 1H), 7.25-7.32 (m, 2H), 7.10 (s, 1H).
NP7-B: productive rate is 8%; ESI[2M+Na]
+: 518.9 (100%);
1H NMR (300MHz, DMSO-d6, TMS): δ 9.49 (d, 1H, J=6.9Hz), 8.91 (d, br, 1H, J=1.8Hz), 8.48 (d, 1H, J=7.5Hz), 7.93 (d, 1H, J=9.3Hz), 7.79 (dd, 1H, J=7.5,4.5Hz), 7.42 (t, 1H, J=7.5Hz), 7.30 (t, 1H, J=6.9Hz), 7.19 (s, 1H).
The structural formula of NP7-A and NP7-B is as follows:
Embodiment 8, indolizino naphthoquinone derivatives NP8's is synthetic
Method is with embodiment 1, and different is with 2,3-two chloro-1, and the 4-naphthoquinones replaces 6,7-two chloro-5, the 8-quinolyl dione replaces 3-fluorine pyridine with pyridine, obtains red crystals indolizino naphthoquinone derivatives NP8.
Productive rate is 43%; ESI[M+1]
+: 320.1 (100%);
1H NMR (300MHz, CDCl
3, TMS): δ 9.82 (d, 1H, J=7.2Hz), 8.29 (d, 1H, J=9.0Hz), 8.22-8.18 (m, 2H), 7.71-7.68 (m, 2H), 7.41 (t, 1H, J=9.0Hz), 7.14 (t, 1H, J=7.2Hz), 4.51 (q, 2H, J=7.2Hz), 1.50 (t, 3H, J=7.2Hz).
The structural formula of NP8 is as follows:
Embodiment 9, indolizino azanaphthalenes quinone derivative NP9's is synthetic
Method is with embodiment 1, and different is with 6, and 7-two chloro-2 quinones replace 6,7-two chloro-5, and the 8-quinolyl dione obtains red crystals indolizino azanaphthalenes quinone derivative NP9.
Productive rate is 26%; ESI[M+1]
+: 340.0 (100%);
1H NMR (300MHz, CDCl
3, TMS): δ 9.97 (s, 1H), 9.86 (s, 1H), 9.50 (d, 1H, J=6.6Hz), 7.22-7.16 (m, 2H), 4.54 (q, 2H, J=7.2Hz), 1.47 (t, 3H, J=7.2Hz).
The structural formula of NP9 is as follows:
Embodiment 10, indolizino azanaphthalenes quinones are to the restraining effect of growth of tumour cell
Select the representative compound of part, with four kinds of tumor cell line: GLC-82 (human lung adenocarcinoma cell), NCI-H460 (National People's Congress's cell lung cancer cell), HL-60 (people's promyelocytic leukemia cancer cells) and MCF-7 (human breast cancer cell) etc. adopt mtt assay to carry out the test of cell in vitro poison.The logarithmic phase cell adds different concns indolizino azanaphthalenes quinones, acts on after 48 hours, measures its absorbancy.Calculate cell growth inhibiting respectively and make a call to 50% o'clock compound concentration, with IC
50Value representation, the result is as shown in table 1.The result shows that the compound of choosing all has the obvious suppression effect in external growth to these four kinds of tumor cell lines.
Table 1 segment bounds I compound is to the restraining effect of tumor cell line growth
IC50μM | ||||
GLC-82 | NCI-H460 | HL-60 | MCF-7 | |
NP1-A | <0.25 | <0.25 | 1.3 | 6.2 |
NP1-B | 1.2 | 1.6 | 5.5 | 7.0 |
NP2-A | 14.2 | 12.2 | 2.4 | >25.0 |
NP2-B | 21.5 | >25.0 | >25.0 | >25.0 |
NP3-A | <0.25 | <0.25 | 0.8 | 6.3 |
NP3-B | 2.4 | 1.9 | 14.4 | >25.0 |
NP4-A | <0.025 | <0.25 | 0.8 | 7.9 |
NP4-B | 1.9 | 1.4 | 14.7 | 12.7 |
NP5-A | <0.25 | 2.1 | 6.5 | 7.3 |
NP5-B | <0.25 | 2.2 | 15.4 | 19.9 |
NP6-A | 1.8 | 0.9 | 16.4 | 16 |
NP6-B | 23.5 | 19.0 | >25 | >25 |
Claims (5)
1. indolizino azanaphthalenes naphthoquinone derivatives, its structural formula is suc as formula shown in (I):
Wherein, M, X, Y and Z are CH or N respectively;
R
1Be selected from following radicals: H, C respectively
1-C
4Alkyl, COOCH
3, COOC
2H
5, COOC
3H
7, COOC
4H
9, COCH
3, COC
2H
5, COC
3H
7, COC
4H
9, CN or aromatic base;
R
2Be selected from following radicals: H, F, Cl, Br, OH, NH respectively
2, COOH or C
1-C
4Alkyl;
R
3Be selected from following radicals: H, F, Cl, Br, OH, COOH or C respectively
1-C
4Alkyl.
2. the preparation method of the described indolizino azanaphthalenes of claim 1 naphthoquinone derivatives is characterized in that comprising the steps:
With 6,7-dichloro azepine naphthoquinones and active methylene group reagent join in the dehydrated alcohol, stir to add pyridine derivate, back flow reaction 5~20 hours down; Stop, cooling has solid to separate out; Filter, the solid that obtains obtains target compound with the silica gel column chromatography separation.
3. preparation method as claimed in claim 2 is characterized in that described active methylene group reagent is Acetacetic acid alkyl ester, itrile group ethyl acetate, methyl ethyl diketone or nitroparaffins.
4. the application of the described indolizino azanaphthalenes of claim 1 naphthoquinone derivatives in preparation treatment cancer drug.
5. application as claimed in claim 4 is characterized in that described cancer is meant human lung adenocarcinoma cell, National People's Congress's cell lung cancer cell, people's promyelocytic leukemia cancer cells or human breast cancer cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100323563A CN101182321A (en) | 2007-12-11 | 2007-12-11 | Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007100323563A CN101182321A (en) | 2007-12-11 | 2007-12-11 | Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101182321A true CN101182321A (en) | 2008-05-21 |
Family
ID=39447760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100323563A Pending CN101182321A (en) | 2007-12-11 | 2007-12-11 | Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101182321A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102093358A (en) * | 2011-02-21 | 2011-06-15 | 中山大学 | Brominated indolizinoquinoline dione derivative and application of brominated indolizinequinoline dione derivative in preparing antibiotic medicament |
CN113501826A (en) * | 2015-01-08 | 2021-10-15 | 美国政府健康及人类服务部 | Furoquinolinediones as inhibitors of TDP2 |
-
2007
- 2007-12-11 CN CNA2007100323563A patent/CN101182321A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102093358A (en) * | 2011-02-21 | 2011-06-15 | 中山大学 | Brominated indolizinoquinoline dione derivative and application of brominated indolizinequinoline dione derivative in preparing antibiotic medicament |
CN102093358B (en) * | 2011-02-21 | 2012-09-05 | 中山大学 | Brominated indolizinoquinoline dione derivative and application of brominated indolizinequinoline dione derivative in preparing antibiotic medicament |
CN113501826A (en) * | 2015-01-08 | 2021-10-15 | 美国政府健康及人类服务部 | Furoquinolinediones as inhibitors of TDP2 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102993148B (en) | Quercetin derivative or its analogue and application thereof | |
CN101362702B (en) | Emodin derivates and application thereof in anti-cancer medicine preparation | |
US20050171138A1 (en) | Flavone acetic acid analogs and methods of use thereof | |
Baruah et al. | Synthesis and cytotoxic activity of novel quinazolino-β-carboline-5-one derivatives | |
TW201212923A (en) | Triterpenoid compounds, benzenoid compounds, and pharmaceutical compositions containing the same | |
CA2470920A1 (en) | Liposomal delivery of vitamin e based compounds | |
CN107417695A (en) | Berbine derivative, its preparation method, pharmaceutical composition and anticancer usage | |
JP2003513079A (en) | Heterocyclic cytotoxic agent | |
JPH08501806A (en) | Process for producing 5,8-dihydronaphthoquinone derivative, novel 5,8-dihydronaphthoquinone derivative and use thereof as anticancer agent | |
EP2805956B1 (en) | Gambogenic acid derivatives, preparation method and application thereof | |
CN108084177B (en) | A kind of jamaicin 9- pyrazole derivatives and its preparation and application | |
WO2017092230A1 (en) | Biflavone compound and uses thereof for treating cancers and preparing drugs | |
CN101182321A (en) | Indolizine heterocyclic nitrogen naphthoquinone derivatives as well as preparation method and anticancer use thereof | |
CN108727329A (en) | N- hydroxyethyl formamide base substituted diphenylamines and xanthene and its application | |
CN108129375A (en) | Compound and preparation method thereof and the application in tumor drug resistance reversal agent is prepared | |
CN102614158A (en) | Emodin derivative with antitumor activity and preparation method thereof | |
CN110590778B (en) | 3, 10 di-p-methoxyphenyl 6, 12 diaza tetracubane compound, synthetic method and pharmaceutical composition | |
Mustafa et al. | Synthesis, antioxidant and antitumor activities of new coumarins grafted to 5-fluorouracil | |
EP3596054B1 (en) | 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments | |
US20090312407A1 (en) | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies | |
CN102531875A (en) | 3-Oxo-1,2-naphthoquinone analogues, preparation method and application thereof | |
CN108640922B (en) | Triazole and diazepine -5- ketone compounds | |
CN109734715A (en) | A kind of efficient DNA target is to anti-tumor drug and its synthetic method and application | |
CN103012394B (en) | Rhodanine derivative and preparation method thereof | |
CN101317845B (en) | Pharmaceutical use of 6-aryl substituted pyridine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20080521 |